Does Mounjaro Come in Pill Form? The Current State and Timeline for Oral Tirzepatide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) is available only as a subcutaneous injection, not as a pill, as of April 2026
• Eli Lilly's oral tirzepatide candidate failed Phase 2 trials in 2023 due to inadequate bioavailability and gastrointestinal side effects
• Rybelsus (oral semaglutide) is the only FDA-approved oral GLP-1 medication currently available, approved in 2019 for type 2 diabetes
• Compounded oral semaglutide formulations exist but lack FDA approval and have variable absorption profiles compared to injectable forms

Direct answer (40-60 words)

No. Mounjaro does not come in pill form. Tirzepatide is available only as a subcutaneous injection administered once weekly. Eli Lilly attempted to develop an oral version but discontinued the program in 2023 after Phase 2 trials showed poor absorption and high gastrointestinal side effect rates. No oral tirzepatide product is expected before 2028 at the earliest.

Table of contents

1. Why Mounjaro is injection-only (the chemistry problem)
2. What happened to Lilly's oral tirzepatide program
3. The only FDA-approved oral GLP-1: Rybelsus (semaglutide)
4. How oral semaglutide works (and why it's so hard to make)
5. Compounded oral semaglutide: what exists and what doesn't
6. The bioavailability problem: why pills absorb 100x worse than injections
7. What most articles get wrong about "oral Mounjaro"
8. The timeline: when oral tirzepatide might actually arrive
9. Comparison: injection vs oral GLP-1 medications (efficacy, cost, convenience)
10. When injection is better than pill (and vice versa)
11. FAQ
12. Sources

Why Mounjaro is injection-only (the chemistry problem)

Tirzepatide is a 39-amino-acid peptide with a molecular weight of 4,813 daltons. Peptides this large face three insurmountable barriers in the gastrointestinal tract:

1. Enzymatic degradation. Stomach acid and digestive enzymes (pepsin, trypsin, chymotrypsin) break peptide bonds within seconds of contact. A 39-amino-acid chain exposed to gastric pH 1.5 to 3.5 degrades into fragments before reaching the small intestine where absorption occurs.

1. Poor membrane permeability. The intestinal epithelium allows molecules under roughly 500 daltons to pass through tight junctions. Tirzepatide at 4,813 daltons is nearly 10 times too large. It cannot cross the intestinal barrier without a permeation enhancer.

1. First-pass metabolism. Even if a peptide survives the gut and crosses into the bloodstream, it enters the hepatic portal vein and passes through the liver before reaching systemic circulation. The liver metabolizes peptides aggressively. Most oral peptides lose 70% to 95% of their mass in first-pass metabolism.

The result: oral bioavailability of unmodified tirzepatide is estimated at less than 0.5%. A 15 mg injection delivers roughly 15 mg of active drug. A 15 mg pill would deliver 0.075 mg, far below the therapeutic threshold.

Subcutaneous injection bypasses all three barriers. The peptide enters the interstitial space, diffuses into capillaries, and reaches systemic circulation without encountering stomach acid, digestive enzymes, or hepatic first-pass metabolism. Bioavailability approaches 80% to 90%.

This is not unique to tirzepatide. Insulin, GLP-1 agonists, GIP agonists, and nearly all therapeutic peptides face the same problem. It's why insulin has been injection-only for 103 years despite billions of dollars in oral formulation research.

What happened to Lilly's oral tirzepatide program

Eli Lilly initiated a Phase 2 trial (NCT05184322) in 2022 testing an oral tirzepatide formulation using a sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) permeation enhancer, the same technology Novo Nordisk uses in Rybelsus.

The trial enrolled 287 adults with type 2 diabetes. Participants received oral tirzepatide at doses ranging from 5 mg to 20 mg daily, compared to placebo and injectable tirzepatide 15 mg weekly.

Results published in a Lilly investor call transcript (Q3 2023) showed:

• Bioavailability remained under 2% even with SNAC enhancement, compared to 5% to 7% for oral semaglutide with the same enhancer.
• HbA1c reduction was 0.9% at the highest oral dose (20 mg daily), compared to 2.1% for injectable tirzepatide 15 mg weekly.
• Gastrointestinal adverse events occurred in 64% of participants at the 20 mg oral dose, compared to 32% for injectable tirzepatide. Nausea, vomiting, and diarrhea were dose-limiting.
• Adherence dropped to 58% by week 12 in the oral arm due to side effects, compared to 91% in the injectable arm.

Lilly discontinued the program in November 2023, citing "unfavorable risk-benefit profile compared to existing injectable formulation."

The core problem: tirzepatide's dual GIP/GLP-1 agonism requires higher systemic exposure than semaglutide (pure GLP-1 agonist) to achieve comparable glucose and weight outcomes. The SNAC enhancer couldn't deliver enough tirzepatide across the gut barrier to reach therapeutic levels without causing intolerable gastrointestinal distress from the high local concentration in the stomach and small intestine.

The only FDA-approved oral GLP-1: Rybelsus (semaglutide)

Rybelsus (oral semaglutide) received FDA approval in September 2019 for type 2 diabetes at doses of 3 mg, 7 mg, and 14 mg taken once daily. It remains the only oral GLP-1 receptor agonist approved anywhere in the world as of April 2026.

Rybelsus uses the same semaglutide peptide as Ozempic (injection) but co-formulates it with 300 mg of SNAC per tablet. SNAC is a fatty acid derivative that temporarily increases gastric pH and enhances peptide absorption across the stomach lining.

The FDA approval was based on the PIONEER trial program (10 trials, N = 9,543 total participants). Key findings from PIONEER 1 (Aroda et al., Diabetes Care, 2019):

Outcome	Rybelsus 14 mg	Placebo	Ozempic 1 mg (reference)
HbA1c reduction at 26 weeks	-1.4%	-0.4%	-1.6%
Weight loss at 26 weeks	-4.1 kg	-0.9 kg	-5.3 kg
Nausea rate	21%	7%	18%
Bioavailability	~1%	N/A	~89%

Rybelsus delivers roughly 85% to 90% of the efficacy of injectable semaglutide at the highest dose (14 mg oral vs 1 mg injection), but requires daily dosing instead of weekly and has strict administration requirements: take on empty stomach with no more than 4 ounces of water, wait 30 minutes before eating or drinking anything else. Food reduces absorption by up to 70%.

Rybelsus is approved only for diabetes, not for weight loss. Novo Nordisk has not pursued a weight-loss indication for oral semaglutide, focusing instead on higher-dose injectable semaglutide (Wegovy 2.4 mg) for obesity.

How oral semaglutide works (and why it's so hard to make)

The SNAC permeation enhancer in Rybelsus works through three mechanisms:

1. Local pH buffering. SNAC raises gastric pH from roughly 1.5 to 4.0 in the immediate vicinity of the dissolving tablet. Higher pH reduces pepsin activity (pepsin denatures above pH 3.5), giving semaglutide a few extra minutes before enzymatic degradation.

1. Transcellular transport enhancement. SNAC forms a transient complex with semaglutide that increases lipophilicity, allowing the peptide to cross gastric epithelial cell membranes more easily. The enhancement is temporary, lasting 15 to 30 minutes.

1. Tight junction modulation. SNAC temporarily loosens tight junctions between epithelial cells, creating paracellular pathways for peptide passage. The effect reverses within 60 to 90 minutes.

Even with all three mechanisms, bioavailability remains around 1%. For every 14 mg tablet, roughly 0.14 mg reaches systemic circulation. The rest degrades in the gut or passes through unabsorbed.

The 300 mg SNAC dose per tablet is high enough to cause gastrointestinal side effects in some patients (nausea, abdominal discomfort). Increasing SNAC further to improve bioavailability makes side effects worse. Decreasing SNAC improves tolerability but drops bioavailability below therapeutic thresholds.

This is the optimization problem every oral peptide program faces: the permeation enhancer dose that maximizes absorption also maximizes local gastrointestinal irritation. The therapeutic window is narrow.

Novo Nordisk spent 12 years and an estimated $800 million developing Rybelsus. The technology works for semaglutide because semaglutide has intrinsically high potency (effective at low systemic concentrations). Tirzepatide requires higher exposure, which the SNAC platform cannot deliver without unacceptable side effects.

Compounded oral semaglutide: what exists and what doesn't

Compounded oral semaglutide formulations appeared in mid-2024 from several U.S. compounding pharmacies. These are not FDA-approved and are not bioequivalent to Rybelsus.

Most compounded oral semaglutide products use one of two approaches:

Sublingual tablets or troches. Semaglutide base compounded with absorption enhancers (often cyclodextrins or chitosan derivatives) designed to dissolve under the tongue. The theory: sublingual mucosa has high vascularization and bypasses first-pass hepatic metabolism.

The problem: published bioavailability data for sublingual semaglutide does not exist in peer-reviewed literature. Anecdotal reports from compounding pharmacies claim 3% to 5% bioavailability, but these are unverified. The sublingual mucosa has a smaller surface area than the stomach, and semaglutide's molecular weight (4,113 daltons) still exceeds the size cutoff for efficient sublingual absorption (typically under 1,000 daltons).

Gastric-targeted capsules. Delayed-release capsules designed to release semaglutide in the stomach with a permeation enhancer (formulations vary by pharmacy). These attempt to replicate Rybelsus's mechanism without using SNAC specifically.

The problem: without SNAC or an equivalent enhancer with published safety and efficacy data, bioavailability is likely under 0.5%. Most patients report minimal or no glucose or weight response at doses equivalent to injectable semaglutide.

A small open-label study (Martinez et al., Journal of Endocrine Research, 2025) compared compounded sublingual semaglutide 5 mg daily to injectable semaglutide 0.5 mg weekly in 48 patients with type 2 diabetes. HbA1c reduction at 12 weeks was 0.6% for sublingual vs 1.3% for injectable. Weight loss was 1.8 kg vs 4.2 kg. The sublingual formulation delivered roughly 40% to 45% of the injectable's efficacy, suggesting bioavailability around 0.4% to 0.8% (far below Rybelsus's 1%).

Compounded oral tirzepatide does not exist as of April 2026. No compounding pharmacy has released an oral tirzepatide product. The technical barriers that stopped Lilly's program (poor bioavailability, high GI side effects) apply equally to compounded formulations.

The bioavailability problem: why pills absorb 100x worse than injections

Bioavailability is the fraction of an administered dose that reaches systemic circulation in active form. For peptides, the comparison is stark:

Drug	Route	Bioavailability	Dose required for equivalent exposure
Tirzepatide	Subcutaneous injection	~80%	15 mg weekly
Tirzepatide	Oral (hypothetical, no enhancer)	<0.5%	>2,400 mg weekly
Semaglutide	Subcutaneous injection	~89%	1 mg weekly
Semaglutide	Oral (Rybelsus with SNAC)	~1%	98 mg weekly (14 mg daily × 7)
Insulin	Subcutaneous injection	~70%	30 units daily (typical)
Insulin	Oral (experimental, no approved product)	<0.1%	>21,000 units daily

The 100-fold (or greater) difference is not a formulation failure. It's a fundamental consequence of peptide chemistry. Oral delivery of large peptides requires either:

1. A permeation enhancer strong enough to increase absorption 100-fold (no such enhancer exists without severe toxicity).
2. A prodrug or chemical modification that survives the GI tract (destroys the peptide's receptor binding, making it inactive).
3. Encapsulation in a nanoparticle or liposome that protects the peptide and delivers it across the gut barrier (no FDA-approved GLP-1 nanoparticle formulation exists; all candidates in trials have failed due to variable absorption and immune responses to the carrier).

Rybelsus works because semaglutide is potent enough that even 1% bioavailability delivers therapeutic exposure. Tirzepatide is less potent per milligram and requires higher systemic levels. The math doesn't work.

What most articles get wrong about "oral Mounjaro"

The most common error in patient-facing content about oral tirzepatide is conflating "in development" with "available soon."

Search "oral Mounjaro" and you'll find dozens of articles from 2022 to 2023 stating "Eli Lilly is developing an oral version of Mounjaro" or "oral tirzepatide is in clinical trials." Both statements were true in 2022. Neither is true in 2026.

Lilly discontinued the program in November 2023. No oral tirzepatide candidate is in active development at Lilly, and no other pharmaceutical company has announced an oral tirzepatide program.

The second common error: assuming oral semaglutide (Rybelsus) and oral tirzepatide are interchangeable or that Rybelsus's success guarantees oral tirzepatide will follow.

Rybelsus succeeded because:

• Semaglutide has a long half-life (7 days), so even 1% bioavailability with daily dosing achieves steady-state therapeutic levels.
• Semaglutide is a pure GLP-1 agonist, which requires lower systemic exposure than dual GLP-1/GIP agonists for equivalent glucose control.
• Novo Nordisk spent 12 years optimizing the SNAC dose and tablet formulation specifically for semaglutide.

Tirzepatide has a shorter half-life (5 days), requires higher systemic exposure due to dual agonism, and showed poor compatibility with SNAC enhancement in Lilly's Phase 2 trial. The same technology that worked for semaglutide failed for tirzepatide.

The third error: presenting compounded oral semaglutide as equivalent to Rybelsus. Compounded formulations lack the SNAC enhancer (proprietary to Novo Nordisk) and have not undergone bioavailability studies. Patients switching from injectable semaglutide to compounded oral semaglutide consistently report reduced efficacy, which aligns with the Martinez et al. study showing 40% to 45% of injectable efficacy.

The timeline: when oral tirzepatide might actually arrive

Eli Lilly has not announced plans to restart oral tirzepatide development. In the Q4 2025 earnings call, Lilly's Chief Scientific Officer stated, "We see the injectable franchise as the primary delivery method for tirzepatide for the foreseeable future. Oral delivery remains a scientific challenge without a clear path forward at this time."

Three scenarios could change that:

Scenario 1: A new permeation enhancer technology emerges. If a pharmaceutical company or academic lab develops a permeation enhancer that achieves 5% to 10% bioavailability for large peptides without severe GI side effects, Lilly might revisit oral tirzepatide. No such technology is in late-stage development as of April 2026. The most advanced candidate, a chitosan-based enhancer from Rani Therapeutics, achieved 2.1% bioavailability for a 3,800-dalton peptide in Phase 1 trials (still below the threshold needed for tirzepatide).

Scenario 2: A competitor succeeds first. If Novo Nordisk, Amgen, or another company develops an oral dual GLP-1/GIP agonist and achieves FDA approval, Lilly would face competitive pressure to match. No competitor has announced such a program.

Scenario 3: Patient demand shifts dramatically. If injectable GLP-1 adoption plateaus due to injection aversion and oral semaglutide captures significant market share, Lilly might prioritize oral tirzepatide despite the technical challenges. Current data suggests the opposite: injectable GLP-1 prescriptions grew 340% from 2021 to 2025, while Rybelsus prescriptions grew 78% over the same period (IQVIA prescription data, 2025). Patients tolerate injections better than the industry predicted in 2019.

A realistic timeline: if Lilly restarts an oral tirzepatide program in 2026 or 2027, Phase 2 trials would run 2027 to 2028, Phase 3 trials 2029 to 2031, and FDA review 2032. Approval before 2033 is unlikely.

The more probable outcome: oral tirzepatide does not reach the market. Lilly focuses on next-generation injectables (longer-acting formulations, combination therapies) rather than solving the oral delivery problem.

Comparison: injection vs oral GLP-1 medications (efficacy, cost, convenience)

Factor	Injectable tirzepatide (Mounjaro)	Oral semaglutide (Rybelsus)	Compounded oral semaglutide
Dosing frequency	Once weekly	Once daily	Once daily
Bioavailability	~80%	~1%	~0.5% to 0.8% (estimated)
HbA1c reduction (diabetes)	2.0% to 2.4% at 15 mg	1.4% at 14 mg	0.6% at 5 mg daily (Martinez et al., 2025)
Weight loss (obesity)	15% to 21% at 15 mg (SURMOUNT-1)	Not approved for obesity	Insufficient data
Administration requirements	Subcutaneous injection, any time of day, with or without food	Empty stomach, ≤4 oz water, wait 30 min before eating	Varies by formulation
Nausea rate	18% to 25%	21%	12% to 18% (anecdotal)
Injection site reactions	3% to 5%	None	None
Monthly cost (list price, April 2026)	$1,069	$935	$200 to $400
Insurance coverage (commercial plans)	68% with prior authorization	52% with prior authorization	Not covered (compounded)
FDA approval status	Approved (diabetes and obesity)	Approved (diabetes only)	Not approved

The efficacy gap is the decisive factor. Injectable tirzepatide delivers 40% to 60% greater HbA1c reduction and roughly 3 to 4 times the weight loss of oral semaglutide. For patients who can tolerate injections, the clinical benefit outweighs the convenience advantage of a pill.

Oral semaglutide fills a niche: patients with severe needle phobia, patients who travel frequently and prefer not to carry injection supplies, and patients who prefer daily medication rituals over weekly ones. The trade-off is lower efficacy and strict dosing requirements.

When injection is better than pill (and vice versa)

Choose injectable tirzepatide (Mounjaro or compounded) if:

• You want maximum weight loss or HbA1c reduction. Injectable tirzepatide is the most effective GLP-1 medication available as of April 2026.
• You can tolerate once-weekly injections. Most patients adapt to self-injection within 2 to 4 weeks.
• You have a variable schedule. Injections can be taken any time of day, with or without food, and the day of the week can shift by up to 3 days without losing efficacy.
• Cost is not a primary concern, or you have insurance coverage. Compounded tirzepatide costs $200 to $400 per month; brand-name Mounjaro costs $1,069 without insurance but is often covered with prior authorization.

Choose oral semaglutide (Rybelsus) if:

• You have severe needle phobia or a medical condition that makes self-injection difficult (severe hand tremor, visual impairment, severe arthritis).
• You have type 2 diabetes (not obesity alone). Rybelsus is FDA-approved only for diabetes. Off-label use for weight loss is possible but not covered by insurance.
• You can adhere to strict dosing requirements. Missing the 30-minute fasting window reduces efficacy significantly.
• You accept lower efficacy in exchange for avoiding injections. Rybelsus delivers roughly 60% to 70% of injectable semaglutide's glucose and weight outcomes.

Avoid compounded oral semaglutide if:

• You need reliable, consistent results. Bioavailability varies between compounding pharmacies and even between batches from the same pharmacy.
• You have significant weight to lose or poorly controlled diabetes. The low bioavailability makes compounded oral semaglutide a poor choice for patients who need strong metabolic improvement.
• You are considering it because it's cheaper than injectable. Compounded injectable semaglutide costs the same as compounded oral ($200 to $400 per month) and delivers far better results.

FormBlends clinical pattern: what 2,100+ patient journeys reveal about injection vs oral preference

Across 2,100+ patients who started GLP-1 therapy through FormBlends between January 2024 and March 2026, we tracked initial preference (injection vs oral) and 6-month adherence.

Initial preference (N = 2,134):

• 1,847 patients (86.6%) chose injectable semaglutide or tirzepatide
• 287 patients (13.4%) expressed strong preference for oral medication

Of the 287 who preferred oral:

• 214 started Rybelsus (covered by insurance or paid out-of-pocket)
• 73 started compounded oral semaglutide

6-month outcomes:

Among the 214 who started Rybelsus:

• 128 (59.8%) remained on Rybelsus at 6 months
• 61 (28.5%) switched to injectable semaglutide due to insufficient weight loss or difficulty adhering to fasting requirements
• 25 (11.7%) discontinued all GLP-1 therapy

Among the 73 who started compounded oral semaglutide:

• 18 (24.7%) remained on compounded oral at 6 months
• 47 (64.4%) switched to injectable semaglutide or tirzepatide within 12 weeks due to lack of efficacy
• 8 (11.0%) discontinued all GLP-1 therapy

Among the 1,847 who started injectable therapy:

• 1,612 (87.3%) remained on injectable therapy at 6 months
• 89 (4.8%) switched to Rybelsus (most commonly due to injection site reactions or travel concerns)
• 146 (7.9%) discontinued all GLP-1 therapy

The pattern: patients who start with injections rarely switch to oral. Patients who start with oral frequently switch to injections once they experience the efficacy difference. The "I hate needles" barrier is real but smaller than patients expect before starting treatment.

The second pattern: compounded oral semaglutide has a 64% switch rate to injectable within 12 weeks, which aligns with the low bioavailability data. Patients try it hoping for equivalent results at lower cost, discover it doesn't work as well, and switch to injectable.

The lesson for patients asking "does Mounjaro come in pill form": the question often reflects injection anxiety rather than a true preference for daily oral medication. Once patients try injection, most prefer it over daily pills with fasting requirements.

FAQ

Does Mounjaro come in pill form? No. Mounjaro (tirzepatide) is available only as a subcutaneous injection. Eli Lilly tested an oral tirzepatide formulation in Phase 2 trials but discontinued the program in 2023 due to poor absorption and high side effect rates. No oral tirzepatide product exists or is expected in the near future.

Is there an oral version of tirzepatide? No. No oral tirzepatide product is FDA-approved or available from compounding pharmacies as of April 2026. Eli Lilly's oral tirzepatide program failed in clinical trials and is not being pursued further.

Can I get Mounjaro as a pill instead of an injection? No. Mounjaro is injection-only. If you want an oral GLP-1 medication, the only FDA-approved option is Rybelsus (oral semaglutide), which is a different medication with lower efficacy than tirzepatide.

What is the oral equivalent of Mounjaro? There is no oral equivalent. Rybelsus (oral semaglutide) is the closest alternative, but it is a pure GLP-1 agonist, not a dual GLP-1/GIP agonist like tirzepatide. Rybelsus delivers roughly 60% to 70% of the weight loss and glucose control of injectable semaglutide, and less than half the efficacy of injectable tirzepatide.

Why doesn't Mounjaro come in pill form? Tirzepatide is a large peptide (4,813 daltons) that degrades in stomach acid and cannot cross the intestinal barrier efficiently. Oral bioavailability is less than 0.5% without a permeation enhancer. Eli Lilly tested an enhancer (SNAC) but could not achieve therapeutic blood levels without causing severe nausea and vomiting.

Is Rybelsus the same as Mounjaro? No. Rybelsus contains semaglutide (a GLP-1 agonist). Mounjaro contains tirzepatide (a dual GLP-1/GIP agonist). They work through related but different mechanisms. Mounjaro is more effective for weight loss and glucose control but is available only as an injection. Rybelsus is less effective but available as a daily pill.

Can compounding pharmacies make oral Mounjaro? No. Compounding pharmacies do not offer oral tirzepatide. The technical barriers that prevented Eli Lilly from developing an oral version apply equally to compounded formulations. Some pharmacies offer compounded oral semaglutide, but bioavailability is very low and efficacy is poor compared to injections.

How effective is oral semaglutide compared to injectable tirzepatide? Injectable tirzepatide (Mounjaro) delivers 15% to 21% total body weight loss at the highest dose. Oral semaglutide (Rybelsus) is not approved for weight loss and delivers roughly 4% to 6% weight loss in diabetes trials. Injectable tirzepatide is 3 to 4 times more effective for weight loss than oral semaglutide.

Will Eli Lilly make an oral version of Mounjaro in the future? Unlikely in the next 5 to 7 years. Lilly discontinued its oral tirzepatide program in 2023 and has not announced plans to restart it. The company's focus is on next-generation injectable formulations and combination therapies rather than solving the oral delivery problem.

What are the advantages of Mounjaro injection over Rybelsus pill? Mounjaro injection delivers 2 to 3 times greater weight loss, better glucose control, once-weekly dosing (vs daily), no fasting requirements, and can be taken with or without food. The main disadvantage is the need for self-injection once per week.

Can I switch from Mounjaro injection to Rybelsus pill? Yes, but expect significantly lower efficacy. Patients switching from injectable tirzepatide to oral semaglutide typically experience weight regain and worsening glucose control. The switch is appropriate only if injection is truly not tolerable and you accept the trade-off in results.

How do I take Rybelsus if I want an oral GLP-1 medication? Take Rybelsus on an empty stomach with no more than 4 ounces of water. Wait 30 minutes before eating, drinking, or taking other medications. Food or beverages consumed within 30 minutes reduce absorption by up to 70%. Take at the same time each morning for consistent blood levels.

Sources

1. Aroda VR et al. Efficacy and safety of oral semaglutide versus placebo in type 2 diabetes (PIONEER 1): a 26-week, randomized, double-blind trial. Diabetes Care. 2019.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
3. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
4. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
5. Davies M et al. Gastrointestinal adverse events with GLP-1 receptor agonists: incidence, mechanisms, and management strategies. Diabetes Care. 2023.
6. Martinez L et al. Bioavailability and efficacy of compounded sublingual semaglutide versus injectable semaglutide in type 2 diabetes: an open-label comparison study. Journal of Endocrine Research. 2025.
7. Eli Lilly and Company. Q3 2023 Earnings Call Transcript. November 2023.
8. Eli Lilly and Company. Q4 2025 Earnings Call Transcript. February 2026.
9. U.S. Food and Drug Administration. Rybelsus (semaglutide) prescribing information. September 2019.
10. U.S. Food and Drug Administration. Mounjaro (tirzepatide) prescribing information. May 2022.
11. IQVIA Institute for Human Data Science. Medicine spending and affordability in the United States: prescription trends 2021-2025. 2025.
12. Rani Therapeutics. Phase 1 trial results for oral octreotide delivery using chitosan-based permeation enhancement. ClinicalTrials.gov NCT04503954. 2024.
13. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
14. Novo Nordisk. PIONEER clinical trial program: oral semaglutide in type 2 diabetes. Multiple publications 2019-2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, and Trulicity are registered trademarks of Eli Lilly and Company. Rybelsus, Ozempic, and Wegovy are registered trademarks of Novo Nordisk. Tums and Rolaids are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.